Johnson & Johnson JNJ

$270.47 +3.33 (1.25%)

Valuation

Market cap
643,088,832,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.61
P/E (forward)
24.53
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
11,925,300
Avg volume
7,611,122
Day's range
$269.47 – $272.50
Shares out
2,407,310,000
Stochastic %K
23%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Techdamentals Nov 21, 3:18 PM
One number from $JNJ's latest report: sales were $25.40 billion in the quarter ended September 27, 2026, up 5.9% from $23.99 billion a year earlier. Net earnings fell to $210 million from $5.15 billion after a one-time charge tied to talc lawsuits. The card lays out revenue, margins, cash and debt from the company's own reported numbers, so see the fundamentals and sign up for free. Educational, not advice. See the fundamentals below 👇 https://techdamentals.com/v3/JNJ?ref=st
0 replies
viggizags Nov 21, 1:17 PM
$BTC.X $SPY pairs trade of the year short buttcoins long Woody Johnson coin $JNJ I said what what....i said what what....i said what what...
0 replies
openclassaction2 Nov 21, 8:11 AM
$JNJ 68,029 talc cases were pending in the mdl as of june 1, per open class actions. no nationwide settlement approved, nothing to claim. the docket is the balance sheet item
0 replies
2Card Nov 20, 10:05 PM
$JNJ FDA issues letter for misleading claims regarding Inlexzos https://www.fiercepharma.com/marketing/jj-draws-fda-rebuke-misstating-inlexzos-bladder-sparing-benefits
0 replies
frb1985 Nov 20, 7:42 PM
$JNJ love my lucky charm. U post and it’s up $4 😆
0 replies
DERICKTRADE Nov 20, 7:35 PM
🟢 $JNJ 11/27/26 $282.5 CALL @ $0.53 Swing Setup 📈 Manage Your Risk (MYR). Wait for confirmation and follow the entry plan.
0 replies
Prime_Pips Nov 20, 7:29 PM
$JNJ 27 NOV 26 $282.5 CALL Entry: $0.53 🚨 ATH breakout in play. Bullish outside bar confirmation. Watching continuation. Risk managed.
0 replies
topstockalerts Nov 20, 6:38 PM
Investors hid out in defensive areas of the market, with retailers such as Walmart and Costco as well as others like Johnson & Johnson and Procter & Gamble seeing gains. Walmart gained almost 3%, while Costco added nearly 2%. Johnson & Johnson and Procter & Gamble each rose more than 1%. “The stock market is going through an AI repricing, reflecting an environment of slowing data center buildouts, reduced funding sources for AI-related projects and a slower trajectory of technology-related earnings growth,” said Richard Saperstein, chief investment officer at Treasury Partners. For the week, the Dow has fallen 6%, putting it on pace for its worst weekly performance since April 2025 in the wake of President Donald Trump’s sweeping tariffs announcement. The S&P 500 has decreased 7%, while the Nasdaq is down about 8%, with both also headed for their largest one-week pullbacks in more than a year. $WMT $COST $JNJ
0 replies